Next Article in Journal
Homeoprotein Msx1-PIASy Interaction Inhibits Angiogenesis
Next Article in Special Issue
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
Previous Article in Journal
The Chromatin Response to Double-Strand DNA Breaks and Their Repair
Previous Article in Special Issue
Identification of Novel Molecular Markers of Human Th17 Cells
Review

Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications

1
Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), 28040 Madrid, Spain
2
Advanced Therapy Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), 28040 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Cells 2020, 9(8), 1852; https://doi.org/10.3390/cells9081852
Received: 1 July 2020 / Revised: 29 July 2020 / Accepted: 5 August 2020 / Published: 7 August 2020
(This article belongs to the Special Issue Molecular and Cellular Basis of Autoimmune Diseases)
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects the lining of the synovial joints leading to stiffness, pain, inflammation, loss of mobility, and erosion of joints. Its pathogenesis is related to aberrant immune responses against the synovium. Dysfunction of innate and adaptive immunity, including dysregulated cytokine networks and immune complex-mediated complement activation, are involved in the progression of RA. At present, drug treatments, including corticosteroids, antirheumatic drugs, and biological agents, are used in order to modulate the altered immune responses. Chronic use of these drugs may cause adverse effects to a significant number of RA patients. Additionally, some RA patients are resistant to these therapies. In recent years, mesenchymal stem/stromal cell (MSCs)-based therapies have been largely proposed as a novel and promising stem cell therapeutic approach in the treatment of RA. MSCs are multipotent progenitor cells that have immunomodulatory properties and can be obtained and expanded easily. Today, nearly one hundred studies in preclinical models of RA have shown promising trends for clinical application. Proof-of-concept clinical studies have demonstrated satisfactory safety profile of MSC therapy in RA patients. The present review discusses MSC-based therapy approaches with a focus on published clinical data, as well as on clinical trials, for treatment of RA that are currently underway. View Full-Text
Keywords: rheumatoid arthritis; mesenchymal stem/stromal cells; clinical trials; cell therapy protocols rheumatoid arthritis; mesenchymal stem/stromal cells; clinical trials; cell therapy protocols
Show Figures

Figure 1

MDPI and ACS Style

Lopez-Santalla, M.; Fernandez-Perez, R.; Garin, M.I. Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. Cells 2020, 9, 1852. https://doi.org/10.3390/cells9081852

AMA Style

Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. Cells. 2020; 9(8):1852. https://doi.org/10.3390/cells9081852

Chicago/Turabian Style

Lopez-Santalla, Mercedes; Fernandez-Perez, Raquel; Garin, Marina I. 2020. "Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications" Cells 9, no. 8: 1852. https://doi.org/10.3390/cells9081852

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop